The diagnosis and treatment of primary vitreoretinal lymphoma: A review

Jose S Pulido, Patrick Bruce Johnston, Grzegorz S Nowakowski, Allessia Castellino, Harish Raja

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Background: To describe the recent diagnostic and treatment options for the most predominant form of primary vitreoretinal lymphoma (PVRL), namely diffuse large B cell lymphoma. This is mainly based on the experience at the Mayo Clinic as well as a partial review of the literature. MYD88 L265P mutation is seen in about 80% of cases; therefore, a polymerase chain reaction for this mutation helps in making the diagnosis that has been notoriously difficult to make. Local therapy using intravitreal methotrexate and rituximab has been very helpful in the treatment of the local disease. Systemic high-dose intravenous methotrexate is helpful in treating bilateral disease in conjunction with intravitreal therapy. Whether it is helpful in preventing or delaying the development of central nervous system lymphoma (CNSL) is still in dispute. If there is development of CNSL or recurrent ocular disease, alternatives to highdose methotrexate under investigation include pomalidomide, stem cell transplantation, or ibrutinib, with or without local therapy. Vitrectomy alone might be helpful as a debulking procedure. Because of the risks of redevelopment of disease, local radiation should be given if other options are not possible. Aqueous levels of IL10 are helpful in following the redevelopment of local disease. Conclusion: Although PVRL is still a difficult disease to diagnose and treat, new advances are helping to make these easier. Larger collaborative studies will be helpful in determining better treatments.

Original languageEnglish (US)
Article number18
JournalInternational Journal of Retina and Vitreous
Volume4
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Lymphoma
Methotrexate
Therapeutics
Central Nervous System
Mutation
Dissent and Disputes
Lymphoma, Large B-Cell, Diffuse
Eye Diseases
Vitrectomy
Stem Cell Transplantation
B-Cell Lymphoma
Interleukin-10
Radiation
Polymerase Chain Reaction

Keywords

  • Diffuse B cell lymphoma
  • Ibrutinib
  • MYD88 L265P
  • Vitreoretinal lymphoma

ASJC Scopus subject areas

  • Ophthalmology

Cite this

The diagnosis and treatment of primary vitreoretinal lymphoma : A review. / Pulido, Jose S; Johnston, Patrick Bruce; Nowakowski, Grzegorz S; Castellino, Allessia; Raja, Harish.

In: International Journal of Retina and Vitreous, Vol. 4, No. 1, 18, 01.01.2018.

Research output: Contribution to journalReview article

@article{896a84ecadc940138dd1b1fb15a83e3a,
title = "The diagnosis and treatment of primary vitreoretinal lymphoma: A review",
abstract = "Background: To describe the recent diagnostic and treatment options for the most predominant form of primary vitreoretinal lymphoma (PVRL), namely diffuse large B cell lymphoma. This is mainly based on the experience at the Mayo Clinic as well as a partial review of the literature. MYD88 L265P mutation is seen in about 80{\%} of cases; therefore, a polymerase chain reaction for this mutation helps in making the diagnosis that has been notoriously difficult to make. Local therapy using intravitreal methotrexate and rituximab has been very helpful in the treatment of the local disease. Systemic high-dose intravenous methotrexate is helpful in treating bilateral disease in conjunction with intravitreal therapy. Whether it is helpful in preventing or delaying the development of central nervous system lymphoma (CNSL) is still in dispute. If there is development of CNSL or recurrent ocular disease, alternatives to highdose methotrexate under investigation include pomalidomide, stem cell transplantation, or ibrutinib, with or without local therapy. Vitrectomy alone might be helpful as a debulking procedure. Because of the risks of redevelopment of disease, local radiation should be given if other options are not possible. Aqueous levels of IL10 are helpful in following the redevelopment of local disease. Conclusion: Although PVRL is still a difficult disease to diagnose and treat, new advances are helping to make these easier. Larger collaborative studies will be helpful in determining better treatments.",
keywords = "Diffuse B cell lymphoma, Ibrutinib, MYD88 L265P, Vitreoretinal lymphoma",
author = "Pulido, {Jose S} and Johnston, {Patrick Bruce} and Nowakowski, {Grzegorz S} and Allessia Castellino and Harish Raja",
year = "2018",
month = "1",
day = "1",
doi = "10.1186/s40942-018-0120-4",
language = "English (US)",
volume = "4",
journal = "International Journal of Retina and Vitreous",
issn = "2056-9920",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - The diagnosis and treatment of primary vitreoretinal lymphoma

T2 - A review

AU - Pulido, Jose S

AU - Johnston, Patrick Bruce

AU - Nowakowski, Grzegorz S

AU - Castellino, Allessia

AU - Raja, Harish

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: To describe the recent diagnostic and treatment options for the most predominant form of primary vitreoretinal lymphoma (PVRL), namely diffuse large B cell lymphoma. This is mainly based on the experience at the Mayo Clinic as well as a partial review of the literature. MYD88 L265P mutation is seen in about 80% of cases; therefore, a polymerase chain reaction for this mutation helps in making the diagnosis that has been notoriously difficult to make. Local therapy using intravitreal methotrexate and rituximab has been very helpful in the treatment of the local disease. Systemic high-dose intravenous methotrexate is helpful in treating bilateral disease in conjunction with intravitreal therapy. Whether it is helpful in preventing or delaying the development of central nervous system lymphoma (CNSL) is still in dispute. If there is development of CNSL or recurrent ocular disease, alternatives to highdose methotrexate under investigation include pomalidomide, stem cell transplantation, or ibrutinib, with or without local therapy. Vitrectomy alone might be helpful as a debulking procedure. Because of the risks of redevelopment of disease, local radiation should be given if other options are not possible. Aqueous levels of IL10 are helpful in following the redevelopment of local disease. Conclusion: Although PVRL is still a difficult disease to diagnose and treat, new advances are helping to make these easier. Larger collaborative studies will be helpful in determining better treatments.

AB - Background: To describe the recent diagnostic and treatment options for the most predominant form of primary vitreoretinal lymphoma (PVRL), namely diffuse large B cell lymphoma. This is mainly based on the experience at the Mayo Clinic as well as a partial review of the literature. MYD88 L265P mutation is seen in about 80% of cases; therefore, a polymerase chain reaction for this mutation helps in making the diagnosis that has been notoriously difficult to make. Local therapy using intravitreal methotrexate and rituximab has been very helpful in the treatment of the local disease. Systemic high-dose intravenous methotrexate is helpful in treating bilateral disease in conjunction with intravitreal therapy. Whether it is helpful in preventing or delaying the development of central nervous system lymphoma (CNSL) is still in dispute. If there is development of CNSL or recurrent ocular disease, alternatives to highdose methotrexate under investigation include pomalidomide, stem cell transplantation, or ibrutinib, with or without local therapy. Vitrectomy alone might be helpful as a debulking procedure. Because of the risks of redevelopment of disease, local radiation should be given if other options are not possible. Aqueous levels of IL10 are helpful in following the redevelopment of local disease. Conclusion: Although PVRL is still a difficult disease to diagnose and treat, new advances are helping to make these easier. Larger collaborative studies will be helpful in determining better treatments.

KW - Diffuse B cell lymphoma

KW - Ibrutinib

KW - MYD88 L265P

KW - Vitreoretinal lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85046793701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046793701&partnerID=8YFLogxK

U2 - 10.1186/s40942-018-0120-4

DO - 10.1186/s40942-018-0120-4

M3 - Review article

AN - SCOPUS:85046793701

VL - 4

JO - International Journal of Retina and Vitreous

JF - International Journal of Retina and Vitreous

SN - 2056-9920

IS - 1

M1 - 18

ER -